CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 145 enrolled
Drug / intervention
SB705498 400 mg +3 moredrug
Likely dose
SB705498 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00281684
NCT00281684Phase 2Completed
CompareCT.gov

A Multi-centre, Randomised, Single Blind, Placebo Controlled, Parallel Group Study to Examine the Effect of Single Doses of SB-705498, a TRPV1 Receptor Antagonist, on Pain Following Third Molar Tooth Extraction

GlaxoSmithKline·interventional·Posted Jan 25, 2006·Updated Jan 28, 2019

In Brief

A Phase 2 clinical trial evaluating SB705498 400 mg, SB705498 1000 mg, and 2 other interventions for Toothache. Completed, enrolled 145 participants across 5 sites in 3 countries.

Detailed Summary

This clinical trial is a multi centre, randomised, single-blind, parallel group, placebo-controlled, single oral dose study with a positive control arm. Patients previously scheduled for 3rd molar tooth extraction, who are otherwise healthy, will be recruited. Upon completion of surgery, e.g. prior to established pain, patients will be randomised to treatment (SB-706598, placebo or co-codamol) and dosed with the study medication

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsToothache
CountriesItaly, South Korea, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 25, 2006
Enrollment StartDec 7, 2005
Primary CompletionOct 3, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.4 years ago

Interventions

SB705498 400 mgdrug

SB705498 400 mg

SB705498 1000 mgdrug

SB705498 1000 mg

Placebodrug

Placebo

Co-Codamoldrug

Co-Codamol